This publication introduces LIVERFASt, a non-invasive biomarker for predicting liver steatosis and fibrosis in patients with chronic Hepatitis B and metabolic syndrome. It demonstrates LIVERFASt’s effective diagnostic performance, particularly outperforming other tools in patients with Type 2 diabetes.